Mechanism based approaches for rescuing and enhancing cognition by Gary Lynch
HYPOTHESIS AND THEORY ARTICLE
published: 15 August 2013
doi: 10.3389/fnins.2013.00143
Mechanism based approaches for rescuing and
enhancing cognition
Gary Lynch1,2* and Christine M. Gall2,3
1 Department of Psychiatry and Human Behavior, University of California, Irvine, CA, USA
2 Department of Anatomy and Neurobiology, University of California, Irvine, CA, USA
Department of Neurobiology and Behavior, University of California, Irvine, CA, USA
Edited by:
Eleanor Dommett, The Open
University, UK
Reviewed by:
Luigia Trabace, University of Foggia,
Italy
Wickliffe C. Abraham, University of
Otago, New Zealand
*Correspondence:
Gary Lynch, Department of Anatomy
and Neurobiology, University of
California, Gillespie Neuroscience
Research Facility, 837 Health
Science Rd., Irvine, CA 92697-1275,
USA
e-mail: glynch@uci.edu
Progress toward pharmacological means for enhancing memory and cognition has been
retarded by the widely discussed failure of behavioral studies in animals to predict human
outcomes. As a result, a number of groups have targeted cognition-related neurobiological
mechanisms in animal models, with the assumption that these basic processes are highly
conserved across mammals. Here we survey one such approach that begins with a form of
synaptic plasticity intimately related to memory encoding in animals and likely operative in
humans. An initial section will describe a detailed hypothesis concerning the signaling and
structural events (a “substrate map”) that convert learning associated patterns of afferent
activity into extremely stable increases in fast, excitatory transmission. We next describe
results suggesting that all instances of intellectual impairment so far tested in rodent
models involve a common endpoint failure in the substrate map. This will be followed by a
clinically plausible proposal for obviating the ultimate defect in these models. We then take
up the question of whether it is reasonable to expect, from either general principles or a
very limited set of experimental results, that enhancing memory will expand the cognitive
capabilities of high functioning brains. The final section makes several suggestions about
how to improve translation of behavioral results from animals to humans. Collectively,
the material covered here points to the following: (1) enhancement, in the sense of
rescue, is not an unrealistic possibility for a broad array of neuropsychiatric disorders; (2)
serendipity aside, developing means for improving memory in normals will likely require
integration of information about mechanisms with new behavioral testing strategies; (3) a
shift in emphasis from synapses to networks is a next, logical step in the evolution of the
cognition enhancement field.
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INTRODUCTION
The term “cognitive enhancement” often refers to attempts at
reducing the intellectual impairments associated with a very
broad array of psychiatric disorders. Recently, however, there has
been considerable discussion about the possibility of extending
the concept to include effects in high functioning individuals
(Turner et al., 2003; Cakic, 2009; Farah et al., 2009; Hyman, 2011).
Questions are being asked not only about feasibility but also about
the ethics and societal consequences of developing agents that
expand human mental capabilities (Darby, 2010; Sahakian and
Morein-Zamir, 2011; Forlini et al., 2013). This surprising surge
of interest likely reflects increased understanding of the synaptic
mechanisms that encode memory, and new information on how
these processes might be disturbed in animal models of various
psychiatric disorders. Notably, work in this field has led to a num-
ber of therapeutic strategies, some of which have progressed to
clinical trials. Success in any of these efforts could result in treat-
ments for persons with congenital or emergent impairments as
well as for potential “off label” use in normals.
In addition to stimulating interest in cognitive enhancement,
the advent of plausible, plasticity-based therapeutics could prove
to be an important conceptual step in the evolution of the field.
Past work largely involved compounds developed for uses not
directly related to memory encoding events but found to improve
learning in animals. The newer approaches target specific links in
the chain of cell biological events leading to persistent synaptic
changes, and thus have the potential to produce agents with rel-
atively selective effects. This specificity could prove to be critical
for translation. The success of neurobiologically grounded strate-
gies does, however, depend on the validity and richness of current
hypotheses about the nature of memory substrates, a topic that
continues to be the subject of some controversy. The present
review will describe a detailed model, much of which is derived
from work using recently introduced imaging techniques, of the
events responsible for the stabilization of long-term potentiation
(LTP) at forebrain synapses in adult rodents. It will be argued that
this “substrate map” explains a great deal of well-documented
LTP phenomenology and as well-provides a new set of timing
rules logically related to a fundamental characteristic of mem-
ory largely ignored by neuroscientists. Subsequent sections will
consider the utility of the working hypothesis in identifying criti-
cal defects in rodent models for a variety of human conditions in
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which memory problems are prominent. Regarding this, we will
use themap to suggest that the animalmodels so far tested all have
a common endpoint failure in the cytoskeletal machinery that sta-
bilizes memory. This conclusion, were it to be correct, would raise
the possibility of broad spectrum cognitive enhancers that rescue
memory, and perhaps cognition, across many different instances
of intellectual disability. Tests of this idea will be described using
a particular class of drugs.
The review next takes up the question of whether treatments
that rescue memory in rodentmodels produce cognitive enhance-
ment in normals. This will incorporate a discussion of why
modifying synaptic characteristics might produce network level
effects that lead to greater cognitive capabilities. Finally, a critical
issue in contemporary work on enhancement concerns the rea-
sons why results obtained with animal models have a poor record
of predicting human outcomes. We will consider this essential
question at various points in the review, beginning with the
following section.
THE PROBLEM OF PREDICTING COGNITIVE EFFECTS IN
HUMANS FROM ANIMAL RESULTS
Research on cellular processes related to cognition necessar-
ily depends on animal, and primarily rodent, studies that face
formidable hurdles with regard to human relevance. For one,
human brains have very different proportions than those of
rodents. Rats are small mammals with expectedly small brains
while humans are among the larger members of the class and
have disproportionately (about 3-fold relative to body weight)
large brains. Differences in brain size are associated with changes
in the proportions of brain regions according to surprisingly
precise allometric rules that apply across the several orders of
mammals (Lynch and Granger, 2008, for a review). Thus, where
cortex constitutes about 30% of the rat brain, the correspond-
ing figure for humans is 80%. And, making matters worse for
translation, the cortical expansion leads to changes in the rela-
tive sizes of specific cortical fields. For example, Area 10, a region
intimately involved in cognitive processing, occupies a much
greater percentage of cortex in man than it does in other primates
(Figure 1) (Semendeferi et al., 2001). These general points have
long been recognized by neuroanatomists and incorporated into
a broad hypothesis referred to as “encephalization of function.”
This idea, which appears to have fallen out of favor, posits that
many functions become progressively more dependent on cortex
than on lower structures as brain size increases. Fulton, in 1941,
described several examples of how discrete cortical lesions pro-
duce increasingly profound and permanent impairments moving
from carnivores to apes, and then to humans (Fulton, 1941).
There is every possibility that the encephalization effect applies
to performance in widely used learning and memory tasks; if so,
treatments that enhance performance in rodents could be acting
on brain structures other than those used by humans to deal with
similar problems.
The above points may account for the much discussed fail-
ure of preclinical studies on memory enhancement to predict
human outcomes (Davis et al., 2008; van der Worp et al., 2010;
Menache, 2012). A long list of compounds improve retention
scores in rodents and, to a lesser extent, monkeys but there are
FIGURE 1 | Cortical areas expand disproportionately with increases in
brain size. Plot shows the relative size of the midbrain (monkeys, apes,
human) and frontal cortical area 10 (apes and human, only) plotted as a
function of overall brain size. As shown, the slope for midbrain is relatively
flat: with a slope of <1 the midbrain occupies a progressively smaller
proportion of brain volume as brain sizes increase. In contrast, with a slope
of >1, Area 10 grows disproportionately to overall volume with increases in
brain volume (Area 10 results from Semendeferi et al., 2001).
no approved treatments for humans. In some cases the failure of
translation can be ascribed to safety questions but this is not the
issue for drugs or everyday compounds in wide use for established
indications. The great disparity between preclinical and clinical
results has prompted neuropsychologists to develop behavioral
paradigms that depend on complex computations that are both
formally similar to those used by humans and associated with
specific cortical structures, in particular hippocampus and frontal
lobe (Demeter et al., 2008; Sauvage et al., 2008; Sarter et al., 2009;
Sauvage, 2010; Lynch et al., 2011). These new behavioral assays
substantially raise the bar for concluding that a given experi-
mental treatment enhances human-like learning in animals; it is
exciting that a small number of clinically plausible drugs appear
to pass these challenging assays (Sarter et al., 2009).
The ongoing development of sophisticated behavioral tech-
nologies for sampling human-like learning in rodents brings to
the forefront the question of what we mean by cognitive enhance-
ment. It is probably fair to say that most, although certainly
not all, of the work in this field makes the assumption that
improving the speed of learning will result in improved cognitive
functioning. This seems reasonable when considering intellec-
tual disabilities but it is not at all clear that the argument will
hold for high functioning individuals. Humans and other ani-
mals incorporate new memory into pre-existing psychological
structures built upon extensive experience with complex environ-
ments, and thereby focus on relevant information while avoiding
what is essentially noise (In these instances, “noise” is defined as
stimuli which vary without consistent relationship to task exe-
cution). It follows from this that simply increasing responsivity
of neural substrates of encoding could have as many negative as
positive consequences for subsequent cognitive operations.
The development of animal tests that relate closely to humans
and are based on homologous cortical regions, while critical
to the future of the enhancement field, raises another and lit-
tle explored question about cognition: how much of everyday
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cognitive performance is captured by the supervised, forms of
learning used in these new tests. One of the great and long
standing questions of experimental psychology revolves around
the question of whether operant learning rules can explain the
rapid, mastering of novel, complex environments. The problem
is of immediate relevance to cognitive enhancement because it is
very likely that much of human cognition involves unsupervised
interactions of this type.
In all, improved animal behavioral protocols will provide far
more challenging preclinical screens for cognitive enhancers than
more commonly used tests. This should greatly improve success
in predicting human efficacy in studies targeting either cognitive
disorders or normal mentation. How well any improvements in
problem solving extend to cognition in the great majority of real
world circumstances is a fascinating follow-on question of great
pragmatic and theoretical interest.
USING PRESUMABLY CONSERVED NEUROBIOLOGICAL
SUBSTRATES AS MEASURES IN THE DEVELOPMENT OF
COGNITIVE ENHANCERS
A great deal has been learned about the synaptic events that
lead to the expression and subsequent stabilization of a form
of synaptic plasticity (LTP) that, from a very large number of
studies using very different experimental approaches, appears to
be critical to the encoding of memory (Bliss and Collingridge,
1993; Morris, 2003; Lynch, 2004b; Lynch et al., 2008, 2010;
Sacktor, 2008). Much of the pertinent synaptic machinery is
found throughout the cortical telencephalon in rodents and pri-
mates, including humans, and it is thus reasonable to assume
that LTP-like effects occur in many regions critical to cogni-
tion. For example, LTP in rodents is commonly induced with
a specific pattern of afferent stimulation (theta burst stimula-
tion: TBS) (Larson and Lynch, 1986; Larson et al., 1986) that
is also effective in promoting learning in human studies using
transcranial magnetic stimulation (Ackerley et al., 2010; Hsu
et al., 2011; Huang et al., 2011). These observations point to
the possibility of using LTP, and the neurobiological mecha-
nisms responsible for it, as a screen for evaluating enhancement
strategies. Thus, while learning may be differentially dependent
on cortical structures in rodents and humans, it may nonethe-
less involve the same neurobiological substrates that have sim-
ilar cross-species reactions to experimental treatments. A great
advantage of this approach with regard to evaluations of cogni-
tive enhancement in cases of learning disorders is that it lends
itself to a two-part strategy in which cellular defects are first
identified in rodent models and then, using the same models,
potential therapeutics are tested for their ability to correct or
obviate those defects. A potential drawback to substrate-directed
experiments is that they assume that improving learning will
either rescue or enhance cognition, something that is not at all
certain.
In this section, we will summarize a model of how LTP is
consolidated. Subsequent portions of the review will then use
this information to describe one implementation of the two-part
strategy mentioned above. We would note that the model, though
incorporating results from many research groups, depends heav-
ily on work from our laboratories; quite different and intriguing
hypotheses have been advanced, most notably by Sacktor and
colleagues (Sacktor, 2008).
CHARACTERISTICS AND SUBSTRATES OF LTP
Essential features of adult LTP, as studied in acute hippocampal
slices, are summarized in Figure 2. Note that theta burst stim-
ulation (TBS; Larson and Lynch, 1986), which mimics patterns
of neuronal firing that occur during learning (Otto et al., 1991;
Buzsaki, 2005; Axmacher et al., 2006), involves very little stimu-
lation (20–40 pulses) and yet leads to significant and enduring
facilitation of EPSPs evoked by subsequent single stimulation
pulses. The potentiation effect thus satisfies the rapid induction
requirement of a memory mechanism. LTP is synapse-specific
(see “control input” to the same dendritic zone in Figure 2) as
required by the enormous capacity of memory. Finally, LTP is
astonishingly persistent, an observation that is only hinted at
by the 5 h slice recordings shown in the figure; LTP has been
shown to last for months using in vivo recordings (Staubli and
Lynch, 1987; Abraham, 2003). It therefore satisfies a third, partic-
ularly demanding requirement for a memory substrate: extreme
stability.
What types of cellular events could produce such exotic, with
regard to duration, physiological effects? Some time ago we pro-
posed that expansion of the synaptic region, due to reorganization
of the actin cytoskeleton, results in an increase in the size of the
post-synaptic receptor pool and thus to enhanced transmission
(Lynch and Baudry, 1988). Direct tests of the idea that TBS trig-
gers the formation of subsynaptic actin networks became possible
FIGURE 2 | Characteristics of long-term potentiation (LTP). Stimulation
was applied to two populations of Schaffer-commissural afferents
converging on the stratum radiatum of field CA1b. Theta burst stimulation
(TBS) delivered to one input (filled circles) causes an immediate increase in
the size of the field EPSP which then decays over about 10min to a plateau
at which the responses are 50–60% elevated above the pre-TBS baseline.
The potentiation persists unchanged for the duration of the recording
session (nearly 5 h in the illustrated case). Note that the second (control)
input, which received only 3/min stimulation pulses, was not affected by
potentiation of neighboring contacts (open circles). Thus, LTP has the
synapse specificity expected for a memory substrate. As with memory
encoding, LTP is initially unstable and readily erased by a number of
treatments (e.g., 5Hz stimulation) but then becomes steadily more
resistant to disruption. Experimental work indicates that this process
involves multiple stages. A rapid phase (“consolidation 1”) has been linked
to reorganization of the sub-synaptic cytoskeleton over the 10min following
TBS; this is followed at about 1h by a newly discovered stabilization event
(“consolidation 2”) involving synaptic adhesion receptors. There is also
considerable evidence for a still later step that depends on protein
synthesis (“consolidation 3”).
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with the development of methods that selectively label actin poly-
mers in living hippocampal slices following induction of LTP (Lin
et al., 2005; Kramar et al., 2006). Studies using this method con-
firmed that TBS causes a marked, NMDA receptor-dependent
increase in the number of spines containing high concentrations
of filamentous (F-) actin (Figure 3) and that this effect lasts for
at least 90min (the longest time tested) (Kramar et al., 2006;
Rex et al., 2009, 2010). It was known from previous work that
toxins which block actin filament assembly prevent LTP consol-
idation (Krucker et al., 2000), a point that we have confirmed
using multiple interventions (see below).
LINKING THETA BURST STIMULATION TO LTP-RELATED
CYTOSKELETAL REORGANIZATION
Transmembrane receptors that bind extracellular matrix pro-
teins (integrins) exert potent effects on the organization of the
FIGURE 3 | Theta burst afferent stimulation (TBS) causes actin
polymerization in dendritic spines. Fluorescent-tagged phalloidin was
infused into living hippocampal slices to label filamentous (F) actin; after
harvest the slices were sectioned for epifluorescence microscopy. (A,B)
Images at left show that spine-labeling (white puncta) is very low in a
control slice but prominent following TBS. At higher magnification (at right)
labeled puncta can be seen to be spines decorating a faintly labeled
dendrite. (C,D) Combining phalloidin labeling with green fluorescent protein
expression allows confocal visualization of phalloidin-labeled puncta within
the heads of clearly defined spines; panels show opaque 3D build of a
single spine (C) and a semi-transparent rendering showing the
phalloidin-labeled aggregate within the spine’s boundaries (D). (E)
Quantification of densely phalloidin-labeled spines at different time points
following TBS shows that numbers are significantly increased, relative to
values in control (cont.) slices, as early as 2min post-TBS and remain
elevated through 60min after stimulation (p > 0.001 for 2–60min vs. cont).
Modified from Kramar et al. (2012b).
submembrane cytoskeleton at adhesion junctions throughout the
body. Given that synapses are the principle adhesion junctions
in brain, integrins were viewed as likely mediators of the strik-
ing increases in spine F-actin produced by TBS. This idea was
all the more attractive because of studies using integrin blocking
with the ligand mimetic peptides, toxins, and genetic manipula-
tions had shown that disruption of integrins thoroughly blocks
hippocampal LTP (Staubli et al., 1990, 1998; Xiao et al., 1991;
Chun et al., 2001; Kramar et al., 2002, 2006; Chan et al., 2003;
Huang et al., 2006; Nagy et al., 2006; Bozdagi et al., 2007) and
the formation of long-term memory (Chan et al., 2003, 2006,
2007; Nagy et al., 2007; Babayan et al., 2012). Direct confirma-
tion that integrins play a critical role in the formation of actin
polymers associated with LTP induction came with studies using
infusions of neutralizing antisera against ß1 integrins, the sub-
type of adhesion receptors found in hippocampal synapses. Those
experiments showed that blocking ß1-family integrins eliminates
both spine actin polymerization and LTP consolidation (Kramar
et al., 2006) (Figure 4). The question then became one of how
the assumed integrin activation by TBS triggered the assembly
and stabilization of actin filaments. Research from cell biologists
has described a number of likely pathways (Miranti and Brugge,
2002; Brakebusch and Fassler, 2003; DeMali et al., 2003; Danen
et al., 2005; Wiesner et al., 2005; Warren et al., 2012) but testing
for these with regard to LTP is difficult because the potentiation
effect occurs in the small percentage of the synaptic popula-
tion affected by conventional stimulation paradigms (see Chen
et al., 2007). Accordingly, we developed a dual immunofluores-
cence method that can be used to reconstruct a large number
of the synapses (labeled with antibodies for the post-synaptic
density protein PSD95) within the field of synaptic potentiation
and so increases the likelihood of detecting, with a second state-
dependent antibody, those contacts containing an activated (e.g.,
phosphorylated) variant of a given actin signaling protein. Using
this Fluorescence Deconvolution Tomography (FDT) method,
and various experimental manipulations (drugs, toxins, genetic)
FIGURE 4 | ß1 integrins are required for TBS-induced LTP and increases
in spine F-actin. Left: Plot shows that potentiation of the
Schaffer-commissural projection to field CA1 is induced with TBS applied in
the presence of the control anti-rat IgG but is blocked with local infusion of
neutralizing antisera to ß1 integrin: note that with ß1 neutralization there is
an initial post-TBS potentiation but the enhanced response rapidly declines
to baseline indicating a failure in consolidation. Right: Quantification of
spines containing dense F-actin in the CA1 field of afferent stimulation
(from in situ phalloidin labeling). As shown, TBS elicits a large increase in
spine F-actin if applied alone or in the presence of anti-rat IgG but this effect
is totally blocked by neutralizing anti-ß1 (∗∗p < 0.001).
Frontiers in Neuroscience | Neuropharmacology August 2013 | Volume 7 | Article 143 | 4
Lynch and Gall Rescuing and enhancing cognition
to target specific receptors and signaling intermediaries, we evalu-
ated activities of actin management and LTP-related proteins that
are concentrated at excitatory synapses. This effort resulted in the
model linking transmembrane receptors to the dendritic spine
actin cytoskeleton described in Figure 5.
The model is complex and there is not sufficient space here
to discuss the individual studies that led to its construction.
However, the arrangements can be broken into three components.
First, three groups of membrane receptors—“modifier,” transmit-
ter, and adhesion—respond directly or indirectly (via AMPA and
NMDA receptors) to TBS. The neurotransmitter and adhesion
groups initiate at least four signaling cascades involving vari-
ous small GTPases, all of which are influenced by the modifier
group. One of these cascades, consisting of RhoA, its effector
ROCK, and ultimately the actin severing protein cofilin, triggers
the formation of new actin polymers in less than 2min follow-
ing TBS. Experiments using various treatments suggest that the
newly formed filaments are initially unstable and can be disas-
sembled by, for example, low frequency afferent stimulation or
adenosine infusion (Rex et al., 2009). The actin filaments become
progressively more stable over 5–10min at which point these
same reversing treatments are no longer effective. We hypoth-
esize that the remaining GTPase driven pathways (i.e., through
Rac/Cdc42, Ras, and Raf) provide for this stabilization, an idea
that has received some experimental support (Rex et al., 2009;
Chen et al., 2010), and also serve to organize the new poly-
mers into structured actin networks. The time frame for this
FIGURE 5 | Hypothesis regarding the links between theta burst
stimulation and the cytoskeletal changes underlying rapid
consolidation of LTP. The model uses three groups of transmembrane
receptors (in blue) for the following: (1) “modifiers” including adenosine
(A1), estrogen (ERB), and BDNF (TrkB); (2) released neurotransmitter (Glut);
and (3) adhesion proteins (integrins). The last of these, working in
conjunction with the modifier group, signal through guanine exchange
factors (Gefs) to the small GTPases (violet) which, in turn, activate
downstream intermediaries (green) leading to actin regulatory proteins (red)
that ultimately control the activity-driven assembly and subsequent
stabilization of actin filaments. There is evidence that the
RhoA-ROCK-Cofilin path controls F-actin assembly whereas Rac and Ras
signaling, including convergence on cortactin, is thought to mediate the
stabilization and elaboration of the actin network.
cytoskeletal stabilization corresponds well with that for the rapid
consolidation of LTP, a process first identified with the same treat-
ments used to disrupt the newly formed filaments (Larson et al.,
1993; Huang et al., 1999). Importantly, interrupting various steps
in the model disrupts the transfer of newly learned material into
long-termmemory (Dash et al., 2004; Rex et al., 2010; Lamprecht,
2011; Babayan et al., 2012; Gavin et al., 2012).
The above collection of results describes well-defined tar-
gets for testing if a putative cognitive enhancer either lowers
the threshold for inducing learning-related synaptic changes or
increases the percentage of activated synapses that exhibit such
effects after supra-threshold stimulation. The combination of
physiological recording and evaluating activities in the multiple
actin regulatory signaling cascades would yield quantitative mea-
sures of selectivity. As discussed next, they would also provide an
organized system with which to search for potential causes of the
learning problems associated with intellectual disabilities and so
a test bed for evaluating the normalizing potential of candidate
cognitive enhancers.
A FINAL COMMON PATHWAY FOR LEARNING
IMPAIRMENTS?
Significant LTP impairments are present in animal models for
an impressive list of human conditions associated with memory
problems (Table 1). We have found defects in components of the
neurobiological substrate model described in Figure 5 in each of
the cases thus far studied. For example, TBS-induced actin poly-
merization is absent, and hippocampal LTP impaired, in mouse
models of early stage Huntington Disease (three models) (Lynch
et al., 2007; Simmons et al., 2009), Angelman syndrome (Baudry
et al., 2012) (Figure 6), inflammation (Tong et al., 2012), and
chronic depression of estrogen levels (Kramar et al., 2009a,b).
The Fmr1 KOmodel of Fragile X syndrome presented an interest-
ing condition in which actin filaments formed after TBS but did
not properly stabilize (Chen et al., 2010). The diverse causes of
the target conditions points to an hypothesis in which failures in
cytoskeletal reorganization initiated by learning-related patterns
of afferent activity, and needed for memory formation, are a com-
mon neurobiological substrate for intellectual impairment in the
different disorders. They also strongly suggest that the conditions
have defects at different sites in the complex machinery leading
to actin filament assembly and/or stabilization. Identifying where
signaling fails will be of great utility in deciding how any cogni-
tive enhancer that normalizes actin network formation, LTP, and
learning produces such effects. The optimal outcome would pre-
sumably be that the therapeutic selectively restores a broken link
in signaling. However, given the overlap in the pathways and thus
likely redundancies, recovery of downstream events could reflect
a circumvention of the defect. In considering these possibilities,
we have used FDT and other methods to investigate signaling in a
subset of the models.
A fairly straightforward explanation can be offered for the
loss of actin signaling and LTP in the case of the Huntington
Disease models: the disease is multiply reported to reduce the
concentrations and trafficking of Brain-Derived Neurotrophic
Factor (BDNF) (Zuccato et al., 2001; del Toro et al., 2006),
which acts on one of the “modifier” receptors (TrkB) described
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Table 1 | Models of human intellectual disability have deficits in LTP
and spine actin management.
Human condition Model Actin Demonstration of
LTP impairment
Huntington Disease HdhQ111, HdhQ92 P Lynch et al., 2007
CAG140 P Simmons et al., 2009
R6/2 Murray et al., 2000
Angelman syndrome Ue3a mutant P Jiang et al., 1998;
Baudry et al., 2012
Low estrogen levels OVX rat P Kramar et al., 2009a,b,
2012a, 2013
Inflammation IL-1ß treatment P Murray and Lynch,
1998; Tong et al., 2012
Fragile X syndrome Fmr1 KO S Lauterborn et al.,
2007; Chen et al.,
2010; Lee et al., 2011
Down syndrome Ts65Dn Costa and Grybko,
2005; Belichenko
et al., 2007
Rett syndrome Mecp2 KO Moretti et al., 2006
Tuberous sclerosis Tsc2+/− von der Brelie et al.,
2006; Ehninger et al.,
2008
All rodent models listed have impairments in the consolidation of hippocam-
pal LTP. For all cases evaluated, disturbances in actin regulation are evident
after theta burst afferent stimulation and involve either a failure in new actin
polymerization (“P”) or in the normal stabilization of new actin filaments (“S”).
in Figure 5. Several groups, including our own, have shown
that sequestering extracellular BDNF disrupts LTP consolidation
(Kovalchuk et al., 2002; Rex et al., 2007); moreover, infusions
of the factor stimulate RhoA signaling leading to actin fila-
ment assembly and LTP (Kramar et al., 2009b, 2013). Indeed,
such treatments fully rescue actin polymerization and potenti-
ation in Huntington Disease model mice (Lynch et al., 2007).
Recent experimental work suggests that inflammation also blocks
BDNF signaling but in this case because interleukin-1ß interferes
with the cascade linking BDNF’s TrkB receptor to downstream
effectors, including cofilin (Tong et al., 2012). Low levels of estro-
gen, and thus under-stimulation of estrogen receptor beta, also
results in a failure of TBS to engage RhoA signaling to cofilin
(Kramar et al., 2009b). Somewhat surprisingly, acute treatments
with the hormone completely rescue TBS-induced actin poly-
merization and LTP in middle-aged rats with long-term ovariec-
tomies (Kramar et al., 2012a). Sustained stress, acting through
the CRHR1 receptor for locally released Corticotrophin Releasing
Hormone, excessively activates RhoA and thereby blocks new
actin filament assembly with TBS (Chen et al., 2013). Normal
aging in rat appears to increase extracellular levels of adeno-
sine and thus cause overstimulation of the post-synaptic A1
receptors (Rex et al., 2005); this is a likely contributor to the
FIGURE 6 | In vivo ampakine treatments rescue TBS-induced spine
actin polymerization and LTP in a mouse model of Angelman
syndrome.Wild type (WT) mice and mutants with a knockout (KO) of the
maternal Ube3a gene (AS mice) were treated with the ampakine CX929 or
vehicle daily for 5 days prior to the preparation of acute hippocampal slices.
(A) In situ phalloidin labeling was used to assess effects of genotype and
treatment on the marked increase in spine F-actin that normally follows
TBS. Images and quantification of F-actin rich (phalloidin-labeled) spines
show that TBS does not increase the number of such spines in slices
prepared from KOs treated with vehicle (veh) relative to counts from slices
receiving control (cnt) low frequency stimulation (LFS) only. In contrast, the
same stimulation applied to slices from KO mice previously treated with
CX929 in vivo (lower right image) elicits a striking increase in F-actin rich
spines that is comparable to that obtained in WTs (lower left image). (B)
Plots of fEPSP responses show that TBS (arrow) elicits initial potentiation in
all groups but the effect slowly decays back to baseline levels in
vehicle-treated Ube3a mutants (ube3a veh). However, slices from mutants
given CX929 in vivo (ube3a cx929) exhibit the conventional LTP effect. (C)
Bar graph shows that context fear conditioning is also rescued in the KOs
treated with CX929 (∗∗p < 0.01 vs. KO veh). Adapted from Baudry et al.
(2012).
loss of LTP in middle aged rats because A1 receptors negatively
modulate TBS-induced RhoA to cofilin signaling and actin poly-
merization (Rex et al., 2009). The RhoA pathway appears to
be intact in the Fmr1 KO Fragile X syndrome model mouse
(Lauterborn et al., 2007) but we have obtained evidence that
TBS fails to engage other GTPases and downstream elements
involved in the stabilization of cytoskeletal changes in these mice
(Chen et al., 2010; Seese et al., 2012).
As expected, impairments to a final common LTP-essential
event (reorganization of the actin cytoskeleton) in models for
conditions with different etiologies are associated with defects
at quite different upstream sites. But surprising generalities are
present as well: excluding Fragile X, all of cases so far studied
involve the RhoA pathway, and in two instances (inflamma-
tion, Huntington Disease) this reflects a problem with BDNF
“transmission.” In line with our expectation that this will hold
for other models in which TBS-induced actin polymerization is
impaired, it was recently reported that synaptic BDNF signaling
through TrkB is markedly attenuated in Ube3a KO (Angelman
syndrome) mice (Cao et al., 2013). However, the results for Fmr1
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KOs indicate that disturbances in the other small GTPase initiated
signaling pathways described in Figure 5 will likely be found as
animal testing proceeds and we suggest that these will ultimately
be linked to processes underlying F-actin stabilization.
Clearly, a great deal more work is needed to characterize sig-
naling impairments in models discussed above and to evaluate
the integrity of these systems in models for other forms of cog-
nitive impairment (e.g., Alzheimer Disease, Down Syndrome).
Nonetheless, the development of a substrate map for rapid con-
solidation has provided a framework for detecting specific links
affected by a diverse array of conditions that disrupt the memory
encoding component of cognition in humans. This constitutes
the first step in the two-part strategy alluded to earlier. We now
turn to the second part: using this information to screen putative
enhancers.
EFFECTS OF POTENTIAL COGNITIVE ENHANCERS ON ACTIN
SIGNALING DEFECTS AND LTP IMPAIRMENTS IN MODELS
OF INTELLECTUAL DISABILITY
Here we will illustrate the idea of using the substrate map for
LTP to evaluate putative cognitive enhancers with regard to the
rescue of memory-related plasticity. The agent to be tested is a
member of the ampakine family, a now sizable class of com-
pounds invented by G. Lynch and G. Rogers (Lynch, 2004a)
widely used in preclinical work. Ampakines are positive allosteric
modulators of AMPA-type glutamate receptors, the mediators
of fast EPSCs throughout the central nervous system, via a
binding pocket located in the interface between each of the
two dimers formed by the tetrameric subunits of the recep-
tors (Jin et al., 2005). This interaction stabilizes the dimeric
configuration and slows deactivation and desensitization of the
receptors following binding of released glutamate. As expected
from this, they significantly prolong open time of the receptor
channel, resulting in enhancement of EPSPs both in slices and
in vivo (Lynch, 2004a; Arai and Kessler, 2007). Ampakines readily
cross the blood brain barrier following peripheral administra-
tion and rapidly increase central AMPA receptor mediated EPSPs
(Staubli et al., 1994a,b).
Administered acutely, ampakines enhance LTP and mem-
ory encoding across different species and testing paradigms
(Granger et al., 1993; Staubli et al., 1994a; Shors et al., 1995;
Rogan et al., 1997; Porrino et al., 2005; Lynch and Gall, 2006;
Hamlyn et al., 2009; Hampson et al., 2009; Simmons et al.,
2009; Lynch et al., 2011). However, our work with models of
intellectual disability has been guided by a second effect they
produce that is directly related to the substrate map: the drugs
up-regulate the production of BDNF (Lauterborn et al., 2000,
2003). This is not an unexpected result because work by Gall
and co-workers (Isackson et al., 1991; Gall, 1992), and other
groups (Castrén et al., 1992; Dragunow et al., 1993; Castren
et al., 1998), demonstrated that increased neuronal firing and
calcium influx (Shieh et al., 1998), as would be caused by
enhanced excitatory transmission, triggers transcription of BDNF
mRNA. Given that BDNF figures prominently in the substrate
map (Figure 5), we asked if increasing brain levels of the factor
with an ampakine rescues actin polymerization and LTP in the
models.
The most extensive tests of the question were conducted
using different models of Huntington Disease. Those experi-
ments produced striking results: in the CAG140 model, four
daily injections with an ampakine elevated hippocampal BDNF
levels as evaluated 24 h after the last treatment (when the
short half-life drug was long removed from circulation) and
at the same time point restored both TBS-induced actin poly-
merization and LTP consolidation (Simmons et al., 2009).
Moreover, long-term object recognition memory was restored
to near normal values in the drug-treated mutants. It is
worth noting here that 7 weeks of daily ampakine injec-
tions beginning in the third post-natal week blocked the
onset of Huntington pathology, including striatal shrinkage,
in the R6/2 model of early onset Huntington Disease and
restored motor performance in a pole climbing test to levels
not detectably different from wild type mice (Simmons et al.,
2011).
The 4 day ampakine treatment regimen also increased BDNF
levels in middle-aged rats and produced the same recovery
of LTP found with acute administrations of the neurotrophin
(Rex et al., 2006). Similarly, daily injections fully rescued TBS-
induced actin polymerization, LTP, and context fear memory
in the Ube3a mouse model of Angelman syndrome, again
in tests carried out 24 h after the last injection of the short
half-life compound (Baudry et al., 2012) (Figure 6). Finally,
and perhaps most remarkably, ampakine pretreatment rein-
stated the TBS-induced RhoA-cofilin signaling, actin polymer-
ization, and LTP consolidation that are otherwise severely
impaired in middle-aged rats with long-term ovariectomy
(Kramar et al., 2012a).
It remains for future studies on these rodent models to take
full advantage of the opportunities afforded by the substrate
map. In particular, and with the notable exception of chronically
reduced estrogen, we have not established that the drug cor-
rects specific signaling defects. In all of the studies, the ampakine
did not affect baseline physiological properties but whether this
holds for the multiple signaling cascades set in motion by TBS
remains to be determined. Put simply, we cannot now say that
the impressive rescue effects are due to rectification of specific
impairments as opposed to activation of alternative pathways.
Nor have we determined how broadly the ampakine affects
transcription of actin regulatory proteins other than BDNF.
Finally, potential ampakine effects on other forms of synaptic
plasticity, such as long-term depression (LTD), are not under-
stood. A single study evaluating this point found that one of
two early variants potentiated NMDA receptor-dependent LTD
induced by extended trains of paired heterosynaptic stimula-
tion (Arai et al., 2004). With these caveats in mind, the results
so far collected are encouraging with regard to the possibil-
ity of treatments that act across a broad spectrum of learning
disorders.
The ampakine strategy for rescuing memory encoding focuses
on the earliest post-synaptic step—fast, receptor mediated exci-
tatory currents—in the complex sequences leading to reorganiza-
tion of the subsynaptic cytoskeleton. An interesting, alternative
approach would be to target downstream steps that are more
directly related to actin management. This could potentially leave
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moment-to-moment synaptic communication unchanged while
overriding defects in the machinery that produces lasting mod-
ifications to individual contacts. Two major difficulties facing
such approaches involve (1) the lack of specificity of agents
acting on enzymes or specific protein-protein interactions, and
(2) the fact that downstream signaling events involved in LTP
(e.g., activation of Src, ERK1/2) are ubiquitous and critical to
many types of cell functions. Nonetheless, there are reasons to be
optimistic that new technologies will eventually overcome these
barriers.
Related to this, the ampakine strategy begins with the assump-
tion that synaptic signaling defects associated with learning
impairments are partial and embedded in a set of higher thresh-
old, redundant pathways. In accord with this idea, enhanced
synaptic drive during patterned afferent activity, as expected with
ampakine treatment, might overcome an elevated threshold in
a defective link in signaling, or engage a normally less respon-
sive parallel cascade. Experiments in progress are evaluating these
possibilities.
COGNITIVE ENHANCEMENT IN NORMALS
The many experiments showing improved memory with diverse
manipulations in different species and across many types of
learning, though not yet having translated into an approved
human treatment, strongly suggest that synaptic encoding
machinery is not maximally efficient under normal circum-
stances. With regard to mechanisms, many of the com-
pounds found to enhance memory are also reported to facil-
itate the induction of LTP, most typically by indirectly facil-
itating NMDA receptor mediated currents. A critical but
rarely discussed question concerns any possible costs of cog-
nitive, or more specifically “encoding,” enhancement either
at the neurobiological level or in behavioral terms. We take
up of this point in the following section and then move
to a consideration of the relationship of memory facilita-
tion to cognitive enhancement. Finally, after having reviewed
a sizable number of studies, we return to the issue (raised
above) of why rodent studies on cognitive enhancement
have such a poor record with regard to predicting human
outcomes.
LTP ENHANCEMENT: ROBBING PETER TO PAY PAUL?
Recent work has uncovered surprising new TBS timing rules
in field CA1 of rat hippocampal slices, the site and prepara-
tion most widely used in studies of LTP. Specifically, delivery
of a second TBS train (TBS2) after a 50–60min delay, but
not earlier, doubles the magnitude of potentiation produced by
TBS1 (Figure 7). TBS3, again delayed by 1 h further increases
percent LTP while TBS4 is largely ineffective (Kramar et al.,
2012b). TBS2 is also effective 90min post-TBS1 and work from
Frey and colleagues, using a more complex stimulation proto-
col, suggests that “LTP2” can be elicited with 4 h delays (Frey
et al., 1995). These results describe a synaptic phenomenon
that is roughly analogous to a fundamental property of learn-
ing; namely, that encoding is substantially improved by divid-
ing training across a series of widely spaced trials (Wickelgren,
1974; Cepeda et al., 2006; Kornell and Bjork, 2008; Callan
FIGURE 7 | Spaced stimulation augments LTP but only with delays of
about 1h. Plots show effects of a first (TBS1) and second (TBS2) round of
theta stimulation on fEPSP responses. (A) TBS1 (black arrow) reliably
increases fEPSPs by about 50% above baseline whereas TBS2 (red arrow)
applied 10 (left), 30 (middle) and 40 (right) min later does not augment the
level of potentiation. (B) TBS2 applied 60min after TBS1 doubles the level
of potentiation. (C) TBS3 further augments potentiation if delayed by
60min whereas a similarly delayed TBS4 has little effect suggesting that
potentiation approaches ceiling levels after 3 spaced theta trains. Modified
from Kramar et al. (2012b).
and Schweighofer, 2010). This spaced trials, or “distributed
practice,” effect is strikingly evident for contextual fear condi-
tioning in rats: learning is markedly improved by using train-
ing episodes separated by 1 h relative to that achieved with
the same training presented in a massed session (Scharf et al.,
2002).
How do enhancing treatments interact with the LTP spaced
trials effect? Acute administration of ampakines both low-
ers the threshold and in some cases raises the ceiling for
LTP1 (Staubli et al., 1994a,b; Arai et al., 1996, 2004; Kramar
et al., 2012b). We confirmed this effect by showing that in
adult rat hippocampal slices a brief ampakine infusion dur-
ing TBS1 greatly increased the percent potentiation (i.e., the
magnitude of LTP1) but then found that LTP2, tested 1 h later
and after ampakine washout, was absent (Figure 8) (Kramar
et al., 2012b). In a sense, then, a single TBS train in the pres-
ence of the ampakine produced both LTP1 and LTP2, at the
expense of further response enhancement by a second stim-
ulation train. This result is interpretable in light of evidence
that under normal circumstances TBS2 greatly expands the
population of spines containing polymerized actin, indicating
that it induces potentiation in synapses that failed to poten-
tiate in response to TBS1. These observations further suggest
that the sampled hippocampal field contains large populations
of contacts with high plasticity thresholds. The argument has
been confirmed in studies using the LTP-like effect produced
by single spine glutamate uncaging. While direct stimulation
produced structural changes to nearly all spines in immature
hippocampal slices, in accord with earlier work (Matsuzaki
et al., 2004; Harvey and Svoboda, 2007; Harvey et al., 2008),
it affected less than half of the tested spines in adult slices
(Kramar et al., 2012b).
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FIGURE 8 | Enhancing LTP1 blocks further increases in potentiation
with a second round of TBS. Theta burst stimulation (TBS) was applied to
the Schaffer-commissural afferents to field CA1b in adult rat hippocampal
slices. Left: Counts of densely phalloidin-labeled spines in the CA1 field of
afferent stimulation show that in the presence of the ampakine CX614
(drug), one round of theta burst stimulation (tbs1) significantly increases the
numbers of spines containing this marker of potentiation above that
induced by TBS alone (∗∗p < 0.01). Right: Plot of field EPSPs shows that
TBS1 (black arrow) applied in the presence of ampakine infusion (black bar)
elicits an LTP effect that is about twice as large as that produced in the
absence of the drug (indicated by dashed line) but a second TBS bout
(TBS2, red arrow) elicits no further potentiation (in contrast to effects of
TBS2 applied under control conditions; see Figure 7B). Modified from
Kramar et al. (2012b).
A number of laboratories have described memory enhance-
ment produced by acute ampakines in rodents, rabbits and pri-
mates, and as tested in a broad range of behavioral paradigms
(Shors et al., 1995; Porrino et al., 2005; Arai and Kessler,
2007; Hampson et al., 2009; Lynch et al., 2011). But, with
a few exceptions noted below, all of this work has used
single training trials or daily sessions dealing with differ-
ent problems. There appear to be no data relating to the
effects of ampakines or other drugs in the context of behav-
ioral practices used routinely, both in research and common
practice, to improve memory. A collapsing of the benefits
of distributed practice on encoding into a single trial, as
expected from the LTP work, would greatly accelerate the
acquisition of strong memory but would also eliminate any
computational advantages of spacing. One psychological hypoth-
esis for the origins of the ubiquitous spaced trials phe-
nomenon posits that spacing restricts the amount of transient,
noisy signals in the final memory. In all, it will be impor-
tant in future work to evaluate costs and benefits of LTP-
related memory enhancers in circumstances where timing rules
are used to maximize the potentiation effect and long-term
memory.
There may be ways of enhancing LTP without sacrificing the
benefits of spaced training. Specifically, there is evidence that
individual synapses have multiple levels of LTP (Enoki et al.,
2009); if so, then it might be possible to increase potentiation
in low threshold synapses without involving the high threshold
contacts used to produce LTP2 and LTP3. This purely spec-
ulative proposition requires the assumption that some factor
that “caps” the amount of potentiation is as work in a con-
ventional, full length train of theta bursts. Removing this cap
would then enhance LTP1 without eliminating LTP2. Given the
results for ampakines, success in testing this string of argu-
ments would likely require LTP enhancers that act indepen-
dently of NMDA receptors. Estrogen represents a good example
of a compound that satisfies this requirement because it facil-
itates elements in the substrate map (specifically, the RhoA-
cofilin sequence) and LTP but not NMDA receptor currents
(Kramar et al., 2009b).
MEMORY DRUGS AND COGNITIVE ENHANCEMENT
If we think of cognition as a process that organizes thoughts
and future actions by integrating new information with already
learned material, then there is no evident reason to assume
that it will be enhanced by manipulations that strengthen mem-
ory encoding. But this perspective ignores the strong like-
lihood that the networks underlying cognitive activities are
themselves products of learning. Thus, two questions about
enhancers and cognition emerge: (1) Do repeated adminis-
trations of memory promoters across many learning sessions
result in new intellectual capabilities? (2) Does acute admin-
istration with such agents produce evidence of enhanced cog-
nition? There are data relating to the first point. Hampson,
Deadwyler and colleagues (Hampson et al., 1998) trained rats
for weeks until asymptotic performance was reached on a com-
plex non-match to sample problem and then introduced every
other day injections of an ampakine. Gradually over 2 weeks the
rats went well-beyond the asymptotic learning scores found in
controls. Detailed analyses showed that this supra-normal per-
formance reflected the acquisition of an ability not found in
controls; specifically, a capacity to suppress the effects of mis-
takes on future learning. These results encourage the idea that
memory enhancement can be used to form behaviorally use-
ful cognitive structures that are beyond the range of control
animals.
There are also reasons to think that memory enhancing
drugs, or at least that category acting on fast EPSCs, will
acutely increase cognitive capacities. It is generally assumed
that cognition involves moment by moment assembly of corti-
cal neurons into networks, from which it could be postulated
that expanding those networks would lead to new capacities.
Experimental work has established that ampakines, as expected
from their mode of action, greatly facilitate throughput in the
tri-synaptic intra-hippocampal circuit (Sirvio et al., 1996), in
essence expanding the network engaged by activation of a sin-
gle input. More impressively, it is reported from PET stud-
ies of well-trained monkeys that injection of an ampakine
during a learning session results in spatially discrete activa-
tion of cortical regions that normally remain silent during a
complex learning problem (Porrino et al., 2005). A fascinat-
ing aspect of these results is that the incorporated associa-
tional region (precuneus area of the midline cortex) is thought
from human work to be a site critical to mental imagining of
the response about to be performed. Notably, learning scores
were greatly improved in drug vs. vehicle trials in the same
monkey.
It will be recognized that the above results involved single stud-
ies and that obvious follow up work is lacking. They do, however,
accord with results showing that pharmacologically increasing
www.frontiersin.org August 2013 | Volume 7 | Article 143 | 9
Lynch and Gall Rescuing and enhancing cognition
fast, excitatory transmission expands networks in slices;
it is thus reasonable to consider the results as sig-
nificant evidence for the possibility of elaborating the
momentary cortical structures used to address complex
problems.
It is widely held that extended training serves to reduce
the number of neurons required to process a given type of
complex information (e.g., Hess et al., 2003; Karlsson and
Frank, 2008). Thus, learning not only encodes information but
increases the efficiency of computation as well. Why, then,
would a drug that elevates activity within a field, and possi-
bly incorporates normally inactive regions into a cortical pat-
tern, enhance performance in a learning trial? The recording
and imaging studies of ampakine effects on learning have, to
date, used well-trained animals dealing with complex prob-
lems of a very familiar type; we can assume that these sub-
jects have already minimized the cortical expenditures needed
for good learning scores. We argue that breaking through the
normal ceiling on performance under these conditions can
be achieved by adding neuronal resources under the guid-
ance of highly efficient (minimized), stable networks built up
over many training sessions. The hypothesis is therefore one
in which learning is posited to create, via LTP-like mecha-
nisms, circuits that are gradually stripped of extraneous elements
by further training, while enhancement beyond normal lim-
its involves transiently and selectively extending these dominant
circuits.
The neural network theory arguments for the above idea are
familiar: the output from a select population of intensely active
cells converges on a second group of neurons but is not sufficient
to bring the targets to firing threshold. Ampakines, by increas-
ing the potency of transmission, allow the learned responses of
the initial cells to activate the secondary group. The expanded
system, driven by a core of sharpened networks, could add new
capabilities, rather than noise, to cortical processing of complex
inputs.
MISSING FEATURES IN ANIMAL STUDIES OF MEMORY AND
COGNITION ENHANCEMENT
Translation is a primary goal of preclinical work on enhance-
ment and it is appropriate to consider a few of what are likely
to be many conditions involved in testing human cognition
that are missing from animal studies. First, and as mentioned
earlier, the animal experiments are concerned with problem
solving in part because of the need for easily quantified behav-
iors and, perhaps, the history of experimental psychology. It is
not at all clear that the solving of particular problems, even
ones that are difficult, represents the bulk of human cognition.
Thought involves the integration of a vast amount of material,
shuffling of the resultant assemblies, and then another attempt
at a satisfactory integration. Salient cues, a limited number of
defined choices, and predetermined rewards are largely lack-
ing in this activity, appropriately described by the 18th cen-
tury philosopher Kant as “free play of the cognitive powers”
(Kant, 1987). It is not obvious, at least to us, that enhanc-
ing scores on puzzles or tasks involving particular computations
will be accompanied by improvements in the fluid world of the
imagination.
Second, the inner environment of humans is one of enormous
complexity, with vast amounts of readily accessible memories,
resulting in a correspondingly large number of free choices at
each step of cognition. We can safely assume that nothing like
this is present in rodents, a point that encapsulates the great dif-
ficulty of predicting human outcomes from preclinical results
obtained with putative cognitive enhancers. Still, rats are pro-
ficient in dealing with a great amount of external complexity
as contained, for example, in real world environments. It is
somewhat surprising then that proposed enhancers aren’t pre-
clinically screened in animals exposed to circumstances where
the number of free choices is high and behavior is unsuper-
vised, somewhat in the manner that holds for human thought.
Complex environments would allow for analysis of how behavior
is self-organized into sequences and whether a potential cognitive
enhancer either accelerates this process or affects the length and
branching of such movement series. A practical advantage would
be that the many different behaviors exhibited by rats in these
conditions would allow for robust analysis of drug selectivity and
side effects.
Third, humans bring a great deal of past experience with dense
internal and external worlds to bear on in-the-moment cognitive
activity. Yet, rats used in enhancement studies, though usually
extensively handled, have nothing like this advantage of expe-
rience when introduced to a testing apparatus. While it is true
that many testing paradigms involve multiple sessions or, in a
few cases, extensive pre-training, there is evidence that a back-
log of generalized experience with rich environments can pro-
foundly affect subsequent performance in novel circumstances.
This could reflect the multiply reported effects of prolonged
stays in enriched environments on forebrain microanatomy and
neurochemistry; put simply, environmental enrichment might
be needed to finish brain development and create something
like a normal state. If so, then the great majority of cognitive
enhancement studies work with a sub-optimal neurobiological
preparation, something that would reduce their relevance to the
fully differentiated human brain. Alternatively, extended inter-
actions with environmental complexity, acting through LTP-like
mechanisms, could result in the creation of cortical networks and
stable cognitive paradigms that are applicable to virtually any type
of situation. Laboratory rats lacking these structures normally
arising from many encounters with real world environments
would constitute a badly flawed model regarding applicability to
humans.
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